Acute Pancreatitis

Acute pancreatitis is a sudden, severe inflammatory condition of the exocrine pancreas characterized by premature activation of digestive enzymes within the pancreatic parenchyma, leading to autodigestion, local inflammation, and a systemic inflammatory response syndrome (SIRS). The disease ranges from mild, edematous interstitial pancreatitis to severe necrotizing pancreatitis with multi-organ dysfunction. In dogs and cats, acute pancreatitis is a common cause of acute abdominal pain, vomiting, and anorexia, and it can be life-threatening. The condition is classified based on histologic severity (interstitial edematous vs. necrotizing) and clinical severity (mild, moderate, severe), with severe cases often associated with pancreatic necrosis, peripancreatic fat necrosis, and systemic complications such as disseminated intravascular coagulation (DIC), acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS).

The etiology of acute pancreatitis in dogs and cats is often idiopathic, but several inciting causes have been identified. In dogs, dietary indiscretion (high-fat meals) is a common trigger, especially in breeds predisposed to hyperlipidemia. Other causes include hypertriglyceridemia (e.g., in Miniature Schnauzers), hypercalcemia (e.g., from neoplasia or primary hyperparathyroidism), trauma (e.g., blunt abdominal trauma), ischemia (e.g., during hypotension or surgery), pancreatic duct obstruction (e.g., from neoplasia, parasites, or sphincter spasm), and certain drugs (e.g., azathioprine, L-asparaginase, potassium bromide, sulfonamides, furosemide, and estrogens). Infectious agents such as Toxoplasma gondii, feline infectious peritonitis (FIP) virus, and pancreatic flukes (Eurytrema procyonis) have been implicated in cats. In both species, genetic predispositions exist, with certain breeds (e.g., Miniature Schnauzers, Yorkshire Terriers, and Cavalier King Charles Spaniels in dogs; Siamese and domestic shorthair cats) showing increased susceptibility. Additionally, endocrine disorders like hypothyroidism, diabetes mellitus, and hyperadrenocorticism may predispose to pancreatitis. In many cases, the exact cause remains undetermined.

Acute pancreatitis is one of the most common pancreatic disorders in dogs and cats. In dogs, the incidence is estimated at 0.1-1% of the general population, but it is higher in certain breeds. Miniature Schnauzers have a breed-specific predisposition due to a high prevalence of hypertriglyceridemia. Other breeds at increased risk include Yorkshire Terriers, Cavalier King Charles Spaniels, Boxers, and Cocker Spaniels. The disease can occur at any age but is more common in middle-aged to older dogs (median age 7-9 years). No sex predilection is consistently reported, though some studies suggest a slight female predominance. In cats, acute pancreatitis is also common, with a reported prevalence of 1-3% in the general population, but it is often underdiagnosed. Cats of any age can be affected, but middle-aged to older cats are more common. No breed predilection is firmly established, but Siamese and domestic shorthair cats may be overrepresented. Geographic and seasonal variations are not well-defined, but dietary factors (e.g., high-fat meals) may contribute to sporadic outbreaks in dogs. Concurrent diseases such as inflammatory bowel disease, cholangitis, and diabetes mellitus are frequently associated with pancreatitis in cats.

The pathophysiology of acute pancreatitis involves a cascade of events beginning with premature activation of trypsinogen to trypsin within pancreatic acinar cells. This activation is triggered by various insults, including ductal obstruction, acinar cell injury, or calcium dysregulation. Trypsin then activates other proenzymes (e.g., chymotrypsinogen, proelastase, phospholipase A2), leading to autodigestion of the pancreas. The release of these enzymes causes acinar cell necrosis, hemorrhage, and inflammation. The inflammatory response is amplified by the release of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1, IL-6, IL-8) and chemokines, which recruit neutrophils and macrophages to the site. This local inflammation can progress to a systemic inflammatory response syndrome (SIRS) when cytokines spill into the systemic circulation, causing endothelial damage, increased vascular permeability, and multi-organ dysfunction. The release of vasoactive mediators (e.g., bradykinin, nitric oxide) leads to vasodilation, hypotension, and shock. Additionally, pancreatic lipase and phospholipase A2 can cause fat necrosis in the peripancreatic tissues and distant sites. Coagulation abnormalities, including DIC, may arise from the activation of the coagulation cascade and consumption of clotting factors. In severe cases, acute kidney injury, acute respiratory distress syndrome, cardiac arrhythmias, and hepatic dysfunction can occur. The severity of the disease depends on the extent of acinar cell necrosis and the magnitude of the systemic inflammatory response.

Predisposing factors for acute pancreatitis include both intrinsic and extrinsic elements. Intrinsic factors include breed-specific genetic predispositions, such as the hyperlipidemia seen in Miniature Schnauzers, which is often due to a mutation in the lipoprotein lipase gene. Other intrinsic factors include hypercalcemia, which can be due to primary hyperparathyroidism, malignancy, or vitamin D toxicity, and endocrine disorders like hypothyroidism, diabetes mellitus, and hyperadrenocorticism, which can alter lipid metabolism and pancreatic function. Age is a risk factor, with middle-aged to older animals more commonly affected. Extrinsic factors include dietary indiscretion, particularly the ingestion of high-fat meals, which can trigger a hypertriglyceridemic response and pancreatic enzyme release. Certain medications, such as azathioprine, L-asparaginase, potassium bromide, sulfonamides, furosemide, and estrogens, have been associated with drug-induced pancreatitis. Trauma, including blunt abdominal trauma or surgical manipulation, can cause pancreatic ischemia and enzyme activation. Infectious agents, such as Toxoplasma gondii in cats and pancreatic flukes in certain regions, can also predispose to pancreatitis. Additionally, concurrent gastrointestinal diseases, such as inflammatory bowel disease, may increase the risk due to altered pancreatic duct drainage and bacterial translocation.

Clinical signs of acute pancreatitis vary depending on the severity of the disease. In mild cases, animals may present with lethargy, anorexia, and mild abdominal discomfort. In moderate to severe cases, the classic signs include acute vomiting, often frequent and persistent, which may be accompanied by diarrhea (sometimes hemorrhagic), and severe abdominal pain. The pain is often localized to the cranial abdomen and may be elicited on palpation, with the animal assuming a 'praying' position (sternal recumbency with forelimbs extended) to relieve discomfort. Other signs include dehydration, fever (or hypothermia in severe cases), tachycardia, tachypnea, and pale mucous membranes due to shock. In peracute cases, animals may collapse and present with signs of systemic inflammatory response syndrome (SIRS), including hypotension, hypoperfusion, and multi-organ dysfunction. In cats, clinical signs are often more vague and may include lethargy, anorexia, and weight loss, with vomiting and abdominal pain being less prominent. Some cats may present with icterus due to concurrent cholangitis or hepatic lipidosis. Physical examination may reveal a tense, painful abdomen, and in severe cases, a palpable abdominal mass due to a pancreatic phlegmon or abscess. Respiratory distress may occur due to ARDS or pleural effusion. Neurological signs, such as seizures or ataxia, may be seen if DIC or electrolyte imbalances occur.

The differential diagnoses for acute pancreatitis include: 1) Gastrointestinal foreign body or obstruction: Presents with acute vomiting and abdominal pain; imaging (radiography, ultrasound) may reveal a foreign body or intestinal obstruction; pancreatitis may be secondary. 2) Acute gastroenteritis (viral, bacterial, parasitic): Often associated with diarrhea and vomiting; fecal analysis and response to symptomatic treatment help differentiate. 3) Gastric dilatation-volvulus (GDV): Typically in large-breed dogs, with acute abdominal distension, non-productive retching, and shock; radiography shows a gas-filled stomach. 4) Peritonitis (septic or chemical): Causes severe abdominal pain and systemic signs; abdominocentesis reveals exudative fluid with bacteria or high protein content. 5) Cholecystitis or cholangiohepatitis: Especially in cats, may cause vomiting, icterus, and abdominal pain; liver enzymes and bilirubin are elevated; ultrasound shows gallbladder wall thickening or biliary sludge. 6) Renal disease (acute kidney injury): Can cause vomiting, dehydration, and abdominal pain; azotemia and abnormal urinalysis are key. 7) Hepatic lipidosis (in cats): Often associated with anorexia and icterus; liver enzymes and bilirubin are elevated; ultrasound shows a hyperechoic liver. 8) Pancreatic neoplasia: May cause similar signs but is often chronic; imaging and biopsy are needed. 9) Mesenteric volvulus or intussusception: Causes acute abdominal pain and vomiting; imaging shows a target lesion or whirl sign. 10) Hypoadrenocorticism (Addison's disease): Can cause vomiting, diarrhea, and weakness; electrolyte abnormalities (hyperkalemia, hyponatremia) and ACTH stimulation test are diagnostic. Definitive diagnosis of pancreatitis is based on specific biomarkers (e.g., canine pancreatic lipase immunoreactivity, cPLI) and imaging findings.

The diagnostic algorithm for acute pancreatitis begins with a thorough history and physical examination. If pancreatitis is suspected, the following steps are recommended: 1) Baseline laboratory tests: Complete blood count (CBC), serum biochemistry profile (including electrolytes, glucose, BUN, creatinine, calcium, liver enzymes), and urinalysis. 2) Specific pancreatic biomarkers: Serum canine pancreatic lipase immunoreactivity (cPLI) or feline pancreatic lipase immunoreactivity (fPLI) is the most sensitive and specific test for pancreatitis. A cPLI > 400 μg/L (dogs) or fPLI > 3.5 μg/L (cats) is consistent with pancreatitis. 3) Abdominal ultrasound: This is the imaging modality of choice; findings include an enlarged, hypoechoic pancreas with hyperechoic surrounding mesentery, and possibly pancreatic abscess or pseudocyst. 4) If ultrasound is inconclusive, computed tomography (CT) may be performed, especially in severe cases, to assess pancreatic necrosis and complications. 5) Additional tests: Serum amylase and lipase are no longer recommended due to poor sensitivity and specificity. C-reactive protein (CRP) may be used as a marker of systemic inflammation. 6) In cases of suspected concurrent disease (e.g., cholangitis, inflammatory bowel disease), additional tests such as bile acid assays, fPLI, and intestinal biopsies may be indicated. 7) If the diagnosis remains uncertain, exploratory laparotomy with pancreatic biopsy may be considered, but this is rarely necessary. The algorithm should also include assessment of severity using clinical scoring systems (e.g., the canine acute pancreatitis severity score) and monitoring for complications such as DIC, AKI, and ARDS.

Laboratory findings in acute pancreatitis are variable but often include: 1) Hematology: Leukocytosis with a left shift is common; in severe cases, leukopenia may occur due to consumption. Hemoconcentration (increased PCV) may be seen due to dehydration, or anemia if hemorrhage occurs. Thrombocytopenia may indicate DIC. 2) Serum biochemistry: Elevated liver enzymes (ALT, ALP) may be seen due to hepatic involvement or bile duct obstruction. Hyperbilirubinemia may occur, especially in cats. Hyperglycemia is common due to stress and decreased insulin release; in severe cases, hypoglycemia may occur due to insulin release from damaged beta cells. Hypertriglyceridemia is a common finding, especially in Miniature Schnauzers. Hypocalcemia may occur and is a negative prognostic indicator. Azotemia (elevated BUN and creatinine) may indicate prerenal or renal causes. Electrolyte imbalances include hyponatremia, hypokalemia, and hypochloremia due to vomiting. 3) Urinalysis: May show glucosuria, proteinuria, or casts if renal injury is present. 4) Blood gas analysis: May reveal metabolic acidosis due to lactic acidosis or alkalosis due to vomiting. 5) Specific biomarkers: cPLI or fPLI is the most specific test; a positive result (cPLI > 400 μg/L, fPLI > 3.5 μg/L) confirms pancreatitis. CRP is often elevated and may correlate with severity. 6) Coagulation profile: Prolonged PT and aPTT, elevated D-dimers, and decreased antithrombin III may indicate DIC. 7) Serology/PCR: In cats, testing for Toxoplasma or FIP may be considered if infectious causes are suspected. 8) Endocrine assays: In cases of suspected concurrent endocrinopathy, thyroid, adrenal, or pancreatic hormone testing may be performed.

Imaging plays a crucial role in the diagnosis and management of acute pancreatitis. 1) Abdominal radiography: May show a loss of serosal detail in the cranial abdomen, a mass effect in the pancreatic region, or a gas-filled duodenum. However, radiography is often normal and is mainly used to rule out other causes of acute abdomen (e.g., foreign body, GDV). 2) Abdominal ultrasonography: This is the preferred imaging modality. Findings include an enlarged, hypoechoic pancreas with irregular margins, hyperechoic mesentery surrounding the pancreas (due to fat necrosis and inflammation), and possibly pancreatic abscess or pseudocyst. Doppler ultrasound may show increased vascularity. In cats, the pancreas may be more difficult to visualize, but the same changes are seen. Ultrasound is also useful to assess the biliary system (e.g., cholangitis, gallstones) and other abdominal organs. 3) Computed tomography (CT): CT is more sensitive than ultrasound for detecting pancreatic necrosis and complications such as abscesses, pseudocysts, and vascular thrombosis. It is particularly useful in severe cases or when ultrasound is inconclusive. 4) Magnetic resonance imaging (MRI): MRI is rarely used but can provide detailed soft tissue contrast and may be helpful in diagnosing chronic pancreatitis or masses. 5) Endoscopy: Endoscopic retrograde cholangiopancreatography (ERCP) is not commonly performed in veterinary medicine but may be used to evaluate the pancreatic duct in chronic cases. 6) Fluoroscopy: May be used to assess gastrointestinal motility or to guide fine-needle aspiration of pancreatic masses. 7) Echocardiography: May be indicated if cardiac complications (e.g., arrhythmias, pericardial effusion) are suspected.

Cytology and histopathology are important for definitive diagnosis and to rule out neoplasia. 1) Fine-needle aspiration (FNA) of the pancreas: This can be performed under ultrasound guidance. Cytology may show inflammatory cells (neutrophils, macrophages), necrotic debris, and occasionally bacteria. However, FNA has a low sensitivity for pancreatitis and may miss focal lesions. 2) Abdominocentesis: If peritoneal effusion is present, fluid analysis may show an exudate with high protein and nucleated cell count, consistent with peritonitis. 3) Histopathology: Pancreatic biopsy is the gold standard for diagnosis. Histologic findings include interstitial edema, infiltration of neutrophils and mononuclear cells, acinar cell necrosis, hemorrhage, and fat necrosis. In chronic cases, fibrosis and atrophy may be seen. Special stains (e.g., Masson's trichrome for fibrosis) can help differentiate acute from chronic changes. Biopsy is rarely performed in acute cases due to the risk of complications, but it may be indicated if the diagnosis is uncertain or if a mass is present.

Treatment of acute pancreatitis is primarily supportive and aims to manage pain, vomiting, fluid and electrolyte imbalances, and systemic complications. 1) Emergency stabilization: In severe cases, intravenous fluid therapy is critical to correct hypovolemia and maintain perfusion. Crystalloids (e.g., lactated Ringer's solution) are preferred, with initial boluses of 20-30 mL/kg in dogs and 10-20 mL/kg in cats, followed by continuous rate infusion (CRI) to replace deficits and ongoing losses. Colloids (e.g., hetastarch) may be used if hypoalbuminemia or hypotension persists. 2) Pain management: Analgesia is essential. Opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl (2-5 μg/kg/h CRI) are commonly used. Non-steroidal anti-inflammatory drugs (NSAIDs) are contraindicated due to the risk of renal and gastrointestinal complications. 3) Antiemetics: Maropitant (1 mg/kg SC q24h) is effective for vomiting. Metoclopramide (1-2 mg/kg/day CRI) may also be used. 4) Nutritional support: Early enteral nutrition is recommended within 24-48 hours if the patient is stable. A low-fat, highly digestible diet is preferred. If oral intake is not possible, a nasoesophageal or esophagostomy tube may be placed. Parenteral nutrition may be considered if enteral feeding is not tolerated. 5) Antibiotics: Antibiotics are not routinely recommended unless there is evidence of bacterial infection (e.g., sepsis, abscess). If indicated, broad-spectrum antibiotics such as ampicillin (22 mg/kg IV q8h) or enrofloxacin (5-10 mg/kg IV/SC q24h) may be used. 6) Management of complications: If DIC occurs, fresh frozen plasma may be administered. If acute kidney injury develops, diuresis and renal support may be needed. In cases of pancreatic abscess or pseudocyst, surgical drainage or percutaneous drainage may be required. 7) Additional therapies: Octreotide (a somatostatin analog) has been used experimentally but is not routinely recommended. Antioxidants (e.g., S-adenosylmethionine) may be beneficial in chronic cases. 8) Monitoring: Serial monitoring of vital signs, hydration status, electrolytes, and renal function is essential. In severe cases, intensive care with continuous monitoring is required.

The prognosis for acute pancreatitis varies widely depending on the severity of the disease. Mild cases have a good prognosis with appropriate supportive care, with most animals recovering within 3-7 days. Severe cases, especially those with pancreatic necrosis, multi-organ dysfunction, or DIC, have a guarded to poor prognosis, with mortality rates reported as high as 20-40% in dogs and 30-50% in cats. Negative prognostic indicators include hypocalcemia, hypoglycemia, severe azotemia, leukopenia, and the development of systemic inflammatory response syndrome (SIRS). Early enteral nutrition and aggressive fluid therapy have been shown to improve outcomes. Recurrence is possible, especially if the underlying cause (e.g., hyperlipidemia, dietary indiscretion) is not addressed. Long-term management may include dietary modification (low-fat diet) and control of underlying conditions.

Follow-up care for acute pancreatitis is crucial to monitor recovery and prevent recurrence. 1) Re-check examinations: Patients should be re-evaluated within 1-2 weeks after discharge. A complete physical examination, including abdominal palpation, should be performed. 2) Serial laboratory monitoring: Serum biochemistry (including electrolytes, glucose, BUN, creatinine, and liver enzymes) and CBC should be repeated at 1-2 weeks and then monthly until normalized. cPLI or fPLI may be repeated to monitor resolution of inflammation. 3) Imaging: Abdominal ultrasound may be repeated at 2-4 weeks to assess pancreatic healing and detect complications such as abscess or pseudocyst. 4) Dietary management: A low-fat, highly digestible diet should be continued long-term. In dogs with hyperlipidemia, a low-fat diet is essential. In cats, a high-protein, low-carbohydrate diet may be recommended. 5) Medication adjustments: If the patient is on long-term medications (e.g., for hyperlipidemia or endocrine disorders), dosages should be adjusted based on monitoring. 6) Owner education: Owners should be advised to avoid high-fat treats and table scraps, and to monitor for signs of recurrence (e.g., vomiting, anorexia, abdominal pain). 7) Long-term monitoring: For patients with chronic or recurrent pancreatitis, regular check-ups every 3-6 months may be recommended, including serial cPLI/fPLI and imaging.

Pearls: 1) cPLI/fPLI is the most sensitive and specific biomarker for pancreatitis; use it early in the diagnostic workup. 2) Early enteral nutrition is beneficial; do not withhold food for prolonged periods. 3) Pain management is critical; opioids are the mainstay. 4) In cats, pancreatitis often occurs concurrently with cholangitis and inflammatory bowel disease; consider a 'triaditis' workup. 5) Hypocalcemia is a negative prognostic indicator; monitor calcium levels closely. 6) Fluid therapy is the cornerstone of treatment; aggressive crystalloid resuscitation is essential. Pitfalls: 1) Do not rely on serum amylase and lipase; they are insensitive and nonspecific. 2) Avoid NSAIDs for pain control; they can worsen renal and gastrointestinal injury. 3) Do not delay nutritional support; prolonged fasting can lead to malnutrition and worsen outcomes. 4) Do not use antibiotics routinely; they are only indicated if there is evidence of infection. 5) Do not overlook concurrent diseases such as hyperlipidemia or endocrinopathies; they must be managed to prevent recurrence. 6) In cats, clinical signs may be vague; a high index of suspicion is needed to avoid misdiagnosis.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for acute pancreatitis: 1) Analgesics: Buprenorphine: 0.01-0.02 mg/kg IV/IM/SC q8-12h; Fentanyl: 2-5 μg/kg/h CRI; Hydromorphone: 0.05-0.1 mg/kg IV/IM q4-6h. 2) Antiemetics: Maropitant (Cerenia): 1 mg/kg SC q24h (dogs and cats); Metoclopramide: 1-2 mg/kg/day CRI (dogs and cats); Ondansetron: 0.1-0.2 mg/kg IV q8-12h (dogs and cats). 3) Gastroprotectants: Omeprazole: 0.5-1 mg/kg PO q24h; Famotidine: 0.5-1 mg/kg IV/PO q12h. 4) Antibiotics (if indicated): Ampicillin: 22 mg/kg IV q8h (dogs and cats); Enrofloxacin: 5-10 mg/kg IV/SC q24h (dogs and cats); Metronidazole: 10-15 mg/kg IV/PO q12h (dogs and cats). 5) Fluid therapy: Lactated Ringer's solution or Normosol-R: initial bolus 20-30 mL/kg (dogs) or 10-20 mL/kg (cats) over 15-30 minutes, then CRI at 2-4 mL/kg/h (dogs) or 1-2 mL/kg/h (cats) to maintain hydration and perfusion. 6) Colloids: Hetastarch (6% HES): 10-20 mL/kg/day CRI (dogs and cats) if hypoalbuminemia or hypotension persists. 7) Nutritional support: Enteral diets: low-fat, highly digestible (e.g., Hill's i/d Low Fat, Royal Canin Gastrointestinal Low Fat); if tube feeding is needed, use a nasoesophageal or esophagostomy tube. 8) Octreotide: 1-2 μg/kg SC q8h (experimental). 9) Antioxidants: S-adenosylmethionine (SAMe): 20 mg/kg PO q24h (dogs and cats). 10) Fresh frozen plasma: 10-15 mL/kg IV over 4-6 hours if DIC or hypoalbuminemia is present. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered (e.g., metoclopramide with opioids may increase sedation).

Key evidence-based literature on acute pancreatitis includes: 1) The ACVIM consensus statement on the diagnosis and treatment of acute pancreatitis in dogs and cats (2016) provides guidelines for diagnosis using cPLI/fPLI and imaging, and emphasizes early enteral nutrition and aggressive fluid therapy. 2) A study by Steiner et al. (2008) demonstrated that cPLI has a sensitivity of 82% and specificity of 95% for diagnosing pancreatitis in dogs, making it superior to serum amylase and lipase. 3) A randomized controlled trial by Mansfield et al. (2011) showed that early enteral nutrition (within 24 hours) improved outcomes compared to delayed feeding in dogs with acute pancreatitis. 4) A study by Parnell et al. (2010) found that hypocalcemia and elevated CRP were negative prognostic indicators in dogs. 5) In cats, a study by Forman et al. (2004) showed that fPLI is highly sensitive and specific for feline pancreatitis, and that concurrent cholangitis and inflammatory bowel disease are common. 6) A meta-analysis by Xenoulis et al. (2014) confirmed that hypertriglyceridemia is a significant risk factor in Miniature Schnauzers. 7) The use of octreotide has been evaluated in experimental models but has not shown consistent benefit in clinical trials. 8) A study by Weatherton et al. (2015) reported that the use of maropitant significantly reduced vomiting in dogs with pancreatitis. 9) The RECOVER initiative (2012) provides evidence-based guidelines for fluid therapy in critical care, which are applicable to pancreatitis patients. 10) A recent study by Cridge et al. (2020) evaluated the use of CT for prognostication in severe pancreatitis, showing that the presence of pancreatic necrosis on CT is associated with a higher mortality rate.